Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Leaning In: From Dialogue to Delivery - What Happens After Milan?

The door is open.

Sustainability was never going to be confined to one room at CPHI Milan. 

Across the event, questions about manufacturing, materials, packaging, energy and the resilience of pharmaceutical supply chains connected with the challenge of making the industry more sustainable. From the Sustainability Spotlight Theatre to Manufacturing 5.0, Packaging & Device Innovation to Global Pharma Outlook… different stages approached a common question. 

How can the industry make its supply chains more sustainable without compromising their ability to deliver? 

The inaugural CPHI Sustainability Summit offered a dedicated space to explore that question. Through presentations, discussions and workshops, it invited delegates to consider not simply what needs to change, but what might make change possible. 

Perhaps that was the most encouraging thing about Milan. 

Not the discovery of new ambitions or the promise of overnight transformation. Much of the thinking, and a good deal of the work, was already under way. 

What mattered was the growing emphasis on putting it to use. Connecting existing initiatives, sharing practical experience and bringing more people into the decisions that determine whether good intentions become everyday business practice.  

The challenge now is to build on that momentum as the clock ticks towards 2030 – a key milestone for global climate commitments and corporate emissions reduction targets. The enormity of what faces the industry is daunting. Yet doing something now – even something relatively small – is better than waiting another year for the perfect answer. 

A bigger conversation 

Before Milan, we asked whether the pharmaceutical industry could begin moving from dialogue to delivery. What would it take to turn ambition into action? Might delegates leave with something to do? 

Across the wider event, sustainability and resilience intersected with innovation, manufacturing efficiency, packaging and supply chain management. 

At the Sustainability Summit manufacturers, suppliers, scientists, procurement specialists and sustainability leaders discussed familiar barriers – cost, data, trust and competing priorities – alongside approaches that organisations are already exploring. 

In a session, Mapping the Supply Chain: Regional Perspectives on Sustainability – moderated by Mary Poddar (Associate Director, Global Business Solutions, 3Degrees)  –Ximena Stawsky (Supply Chain Head, Core Markets, Europe, Australia, South Korea & Japan, Merck), Beatrice Eccidio (Chief Procurement Officer, Zentiva) and José-Francisco Vallejo Carrera (Head of Environment & Environmental Sustainability, Sanofi) explored the relationship between sustainability and supply chain resilience. From reusable packaging trials to environmental risks such as water scarcity, the discussion highlighted the challenges of making informed decisions across complex supply networks. 

Beyond the Summit, the wider CPHI programme reflected these intersecting priorities.  

In the Manufacturing 5.0 Theatre, CDMO Consolidation: Strategic Partnerships or Dangerous Dependencies, moderated by Bernardo Estupiñán (Managing Partner, CDMO Advisor LLC) and featuring Kristina Kölerud (Senior Director External Manufacturing, Global Supply Chain, Leo Pharma), Chris Ballas (Global Commercial Lead, Cook MyoSite), Hannah Spaepen (Global Head CMC Portfolio Management, Thermo Fisher Scientific) and Philip Coetzee (Director CMO Management, Daiichi Sankyo Europe GmbH), explored the balance between closer manufacturing partnerships, supply chain resilience and contingency planning. Meanwhile, in From Global to Local: Building Resilient Pharma Supply Chains Through Local-for-Local Manufacturing, Jennifer Dragan (Director for Global Business Development, Contract Manufacturing) and Philippe Drechsle (Vice-President, Commercial Product Strategy, Region Europe, International and APAC) both from Fresenius Kabi, examined how regional manufacturing can strengthen supply continuity while maintaining global efficiency. 

On the Supply & Formulation Excellence stage, Pressures and Strategic Imperatives of Resiliency: Rethinking Pharma Supply Chains featured Ronald T Piervincenzi (CEO, United States Pharmacopeia USP) who examined how geopolitical pressures, national policies and cost considerations are reshaping supply networks. A subsequent session – API Security in a Fragmented World: Navigating the New Global Supply Chain Reality, featured Pushpa Vijayaraghavan (Director, Sathguru Management Consultants), Carlos Gusmon (Vice-President, Global Procurement, Regeneron), Abdelaziz Toumi (CEO, Lupin Manufacturing Solutions), S Leigh Verbois (CEO, Rx-360) and David Seignolle (CEO, EUROAPI), delved into the practical challenges of identifying supply dependencies, diversifying sourcing and securing access to critical medicines. 

Elsewhere, stages including Next-Gen Bio, Packaging & Device Innovation, Global Pharma Outlook, AI & Tech, and Contamination Control offered further perspectives on the challenges facing pharmaceutical and supply chains. Together, the wider programme provided useful context for the Summit’s discussions, connecting sustainability with the industry’s broader operational and commercial priorities. 

Back at the Sustainability Spotlight Theatre, The Sustainability Power Hour brought existing initiatives into view across healthcare plastics, green chemistry, clinical pathways, supplier expectations and circularity. 

Together, they offered a picture of an industry already working on solutions, often through different organisations and partnerships. The opportunity now is to connect those efforts, share what is being learned and help more businesses put that knowledge to work. 

Courage Meets Commerce 

In The Advocate & the Enabler: a Fireside Reality Check on Sustainability, Magnus Blomberg (Senior Director, Sustainability Technologies Innovation, AstraZeneca) and Nic Hunt (Group Head of Sustainability, Nelipak Healthcare Packaging and Executive Committee Member, Healthcare Plastics Recycling Council) moderated by Carly Santer (Founder & Director, Future Delta, and Strategic Advisor, Sustainable Healthcare Coalition), explored the courage needed to challenge established practices, bring colleagues on board and make change happen within an organisation. 

The message was encouraging: meaningful progress often begins with someone willing to question the way things have always been done. But courage alone won’t decarbonise a supply chain or persuade a procurement director to release funding. 

Which is why some of the most interesting questions in Milan were practical ones. Who pays? Who carries the risk? How do suppliers respond to new expectations without simply inheriting the burden? How might more sustainable choices also support the security, flexibility, and long-term resilience of supply chains? 

The symbiotic relationship is not automatic. We already know that a greener alternative may bring additional costs, technical challenges or new dependencies, but it may also open conversations about energy security, material use and exposure to future risks. 

Something people can use 

A session at the Stella Polare Auditorium explored what the speakers called Positive Pressure: How Clients and Suppliers Can Move the Needle on Emissions Reduction between customer and supplier. Robert Williams (Senior Director, Sustainable Procurement, AstraZeneca) and Hywel Woolf (Global Sustainability Manager, Sharp Services) discussed sustainability expectations alongside security of supply, cost stability, transparency and longer-term planning. 

They described a collaborative approach – based on transparency about the shared challenges faced by both customer and supplier and how this transparency can be used to leverage change.  The realisation being: setting a target is not the same as working through what it will take to meet one. 

The Sustainability Power Hour, as previously mentioned, offered a sweep of activity across the value chain. The Healthcare Plastics Recycling Council discussed plastics and recovery. The Sustainability Healthcare Coalition outlined approaches to understanding environmental impacts in care pathways and clinical trials. Other initiatives explored circularity, shared supplier expectations, and value chain efficiencies. 

Elsewhere, Isamir Martínez (Assistant Director, ACS Green Chemistry Institute, American Chemical Society), alongside Dr Olivier Dapremont (Executive Director, Technology & Innovation, SK pharmteco) explored approaches to greener choices in pharmaceutical chemistry, including available resources intended to help scientists assess options in everyday development work. 

A presentation from Camille Messer (Global Head of Sector Initiatives, EcoVadis) on the Responsible Health Initiative raised another practical frustration: the time suppliers spend responding to overlapping sustainability requests. The shared-assessment approach aims to reduce duplication. 

An Alliance to Zero workshop on financing greener alternatives considered how costs, risks and contractual agreements might be shared. A session: Scope 3: How Leading Pharma Organisations are Moving From Strategy to Action to Decarbonise Their Supply Chains - Clean Heat involving AstraZeneca, ERM and Secaro explored technical and commercial considerations around lower-carbon industrial heat, including investment, efficiency and energy security. 

Milan brought working models, tools, proposals and difficult questions into view… not finished answers. 

Taken together, they suggested something important: progress may depend as much on making change easier to undertake as on persuading people that change is necessary. 

Sustainability teams understand the issues intimately, yet whether they can take action can depend on decisions made elsewhere – by finance, procurement, operations and the people determining investment priorities. 

A promising initiative needs a champion. It also needs a business case that colleagues outside the sustainability loop can recognise. 

Perhaps this is where sustainability and resilience find common ground; not in assuming they always deliver the same benefits, but in examining where the commercial and environmental arguments genuinely reinforce one another.

Stay Connected

Get the latest news, event updates, and product announcements delivered straight to your inbox.

You can opt out at any time by clicking unsubscribe or contacting us or the sender. For further details, see our Privacy Notice.

What leaves Milan? 

An event cannot establish that these approaches will work everywhere, or that good intentions will survive the next budget meeting. Questions will always remain about evidence, cost, scale and uptake. 

However, there is room for hope. Not because the industry’s sustainability or supply chain challenges have been solved, but because possible next steps have been brought into view. 

The Sustainability Summit provided space to examine those possibilities. The wider CPHI Milan programme connected them with manufacturing, packaging, devices and the everyday realities of pharmaceutical supply. 

This wider reach matters. Sustainability cannot remain the responsibility of specialists alone. Its future depends on decisions about procurement, production investment and the security of supply. 

Before Milan, we asked Silvia Forroova (Director – Partnerships & Sustainability, Informa) and Peylina Chu (Chair, CPHI Sustainability Collective’s Steering Committee) what they hoped the Summit and the wider event might achieve? Afterwards, we asked what they would like to see happen next. 

“What I’d really like to see now is people sharing how the Sustainability Summit – and CPHI Milan as a whole – helped them make new connections, discover something useful or find someone they can work with. We want to build momentum working with our community, exhibitors and partners to keep sustainability and supply chain resilience at the heart of the conversation… and help turn those conversations into something meaningful.” commented Silvia Forroova. 

Peylina Chu agreed, the real measure of Milan’s success will be what happens after everyone has gone home. 

“I’d love to see people acting on what they learned and who they met,” she said. “That might mean a new partnership, a sustainable solution being adopted, or a tool from one of the workshops becoming part of everyday practice. It could mean joining forces with industry groups such as PSCI, HPRC or Alliance to Zero. That’s when we’ll know the Summit has made a practical difference. When the conversations turn into something people actually do." 

 Before Milan, we suggested that perhaps the most valuable thing delegates could take away was something to do. Well, there are certainly things to consider doing. 

A conversation with a supplier. A tool to investigate. A partnership to learn from. A business case that finally reaches the right desk. 

Small steps, perhaps. But small steps make larger ones possible. 

The fuller story – what succeeds, what stalls, what can be learned across the industry – will take longer to tell. 

For now, the door is open. The question is who steps through it… and what they decide to do.  

After all, what happened in Milan shouldn’t stay in Milan.